Register for Regeneron’s Webcast This Coming Sunday, February 13, Providing Update on VEGF Trap-Eye Clinical Studies

February 11, 2011

Regeneron Pharmaceuticals recently announced that it will webcast an investor briefing this coming Sunday, February 13, 2011 from 9 a.m. to 10:30 a.m. Eastern Time.  At the investor briefing, principal investigators from the VEGF Trap-Eye clinical studies will recap presentations from the Bascom Palmer Eye Institute’s Angiogenesis, Exudation and Degeneration 2011 meeting being held in Miami, Florida on Saturday, February 12.

The investigator presentations will provide additional data from the VIEW 1 and VIEW 2 Phase 3 trials in patients with the neovascular form of age-related macular degeneration (wet AMD), the COPERNICUS Phase 3 trial in macular edema due to central retinal vein occlusion (CRVO), and the DA VINCI Phase 2 trial in diabetic macular edema (DME). Regeneron reported positive top-line results from all these trials in the fourth quarter of 2010.

Prior registration is required to participate in the webcast. Click here to register for the webcast.




Jump down to form below to submit your own comments

Comments are closed.